Exclusive: How a Swiss pharma got to Octozi's cap table before any US VC did — TFN

Octozi secured $3M led by Surface Ventures after Swiss pharma Debiopharm invested pre-seed, leveraging industry connections to accelerate clinical data AI adoption.

Raccontata datechfundingnews.com